Navigation Links
Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology
Date:12/11/2007

tta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, and the timing of launch of Rosetta's first diagnostic products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing it
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
9. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...re/ -- The world,s first concept demonstration t...ugh alternative to replace a petrochemically produ...ber with renewable biomass, made their debut in Co...display at a lounge in the common departure area a...December 21, while the other tire will make appear...
(Date:12/2/2009)...swire-FirstCall/ - Oncolytics Biotech Inc. ("Oncol...announced today that in connection with its previo...e exercised in full their over-allotment option an... is comprised of one common share and 0.4 of a com...e of US$3.00 per unit. Each whole common share pur...
(Date:12/2/2009)...s, December 2 Pepscan Holding NV,...ng on protein mimicking,technology for the generat...,has appointed Wim E.M. Mol, Ph.D. as new Chief Ex...sible for all of Pepscans corporate functions and,...the company. He brings to,Pepscan more than 20 yea...
(Date:12/2/2009)... December 2 Gamida Cell announced ...al (animal study) safety and,efficacy of a gene th...,Cornell Medical College and Gamida Cell. The prod...such as Cooley,s Anemia. , Gamida Cell is... vivo,populations of stem/progenitor cells. The c...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Dutch Biotech Company Pepscan Appoints New CEO 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...today,announced the appointment of industry vetera... further bolstering its position as a leader in th...Mr. Bailye, 54, recently retired from his position... Dendrite was acquired by French information,provi...te, a pharmaceutical,sales force automation system...
...HERAL VASCULAR DEVICE MARKET INSIGHTS WEBINAR ... Thursday, June 5, 2008, 11 am US Eastern Ti...s), PRESENTER: Stephanie LaBelle, Analyst from ...e the link below to register or call Shiu-Yik Au a...Research Group presents a complimentary Webinar ou...
...ire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT...t its 12-patient,Phase I clinical study entitled "...todynamic Therapy of Actinic Keratosis" has met bo...re delighted to have received, for the first time,...in a dermatological application,",said Madi R. Mad...
Other Biology Technology:IntegriChain Appoints John Bailye to Its Board of Directors 2Peripheral Vascular Device Market Insights Webinar 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:12/3/2009)... investment in energy efficient technologies resea...h Council (EPSRC) Chief Executive Dave Delpy belie...ng research has already brought us fuel cells, mar...stment is needed to develop the capabilities of di...ssion targets by 2020 and limit the impact of clim...
(Date:12/2/2009)...ino men have a more difficult time quitting smokin...ture, but acculturation has no affect on Latinas o... are published in Cancer Epidemiology, Biomarkers...ion for Cancer Research. The December issue has a ...ts smoking cessation differently for Latino men an...
(Date:12/2/2009)...cents exposed to cigarette smoking scenes in movie... and this may be part of the acculturation process...new study findings. , "Our study supports an R-r...hts the global implementation of the World Health ...ol, which includes guidelines for countries to res...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 1Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 2Blood Clot Threat After Surgery Worse Than Thought 62571 1Blood Clot Threat After Surgery Worse Than Thought 62571 2Blood Clot Threat After Surgery Worse Than Thought 62571 3Blood Sugar Intolerance May Predict Postpartum Ills 62567 1Blood Sugar Intolerance May Predict Postpartum Ills 62567 2
...TON, DC -- Sweetpotatoes, often misunderstood and ...saving food crop in developing countries. , Accor...tato.org ), more than 95 percent of the global swe...ere it is the fifth most important food crop. Desp...e potato. Potatoes are tubers (referring to their ...
...ts have identified a new way to breed brassicas, w...esistant to a damaging virus. Their discovery has ... be durable, broad-spectrum and unlikely to be ove...(TuMV) is an economically devastating virus that i...cially brassicas. In research published recently i...
...ama Barkai will receive the Helen and Martin Kimme...v. 5 at the Weizmann Institute. The award is accom...er five years. , Taking a chance on an experiment.... Living cells are, from this angle, great subject... have all sorts of interesting consequences for ma...
Other Biology News:Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 2Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 3Genes identified to protect brassicas from damaging disease 2Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2
Biolase Core Kit from Bioline
...amplification of GC-rich nucleic acids ,The GC-... a proofreading polymerase, powers through templat...h other polymerases and other blends of polymerase...unique GC-RICH Resolution Solution combine to deli...
...nogen: synthetic peptide corresponding to the thir..., conjugated to KLH. The immunizing peptide has 79...form: Solution in phosphate buffered saline, pH 7....d: IHC (p). Titertest values: immunohistochemistr...
CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)
Biology Products: